Vadim S. Koshkin, MD, on Sequencing Enfortumab Vedotin With ICI for Advanced Bladder Cancer
MedPage Today,
This Reading Room is a collaboration between MedPage Today® and: Does the last systemic therapy given prior to enfortumab…
Enfortumab Vedotin Plus Pembrolizumab Sustains Long-Term Benefit in Metastatic Urothelial Carcinoma
OncLive,
Shilpa Gupta, MD Long-term efficacy and safety data from the phase 1/2 EV-103 trial (NCT03288545) evaluating enfortumab vedotin-e…
Frontline Enfortumab Vedotin/Pembrolizumab Shows Continued Efficacy in Advanced Urothelial Carcinoma at 4-Year Follow-Up
Oncology Nursing News,
Shilpa Gupta, MD Combined treatment with enfortumab vedotin-ejfv (Padcev, EV) and pembrolizumab (Keytruda) continued to…
Enfortumab Vedotin Combo Shows Activity in Metastatic Urothelial Carcinoma
Cancer Network,
"In EV-103 dose escalation/cohort A, the safety profile of the combination was manageable, with no new safety concerns observed…